BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34509979)

  • 1. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Revia S; Seretny A; Wendler L; Banito A; Eckert C; Breuer K; Mayakonda A; Lutsik P; Evert M; Ribback S; Gallage S; Chikh Bakri I; Breuhahn K; Schirmacher P; Heinrich S; Gaida MM; Heikenwälder M; Calvisi DF; Plass C; Lowe SW; Tschaharganeh DF
    Gut; 2022 Aug; 71(8):1613-1628. PubMed ID: 34509979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
    Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
    Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1407-1413. PubMed ID: 28698146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
    Leng X; Wang J; An N; Wang X; Sun Y; Chen Z
    Oncogene; 2020 Oct; 39(41):6468-6479. PubMed ID: 32879445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
    Tran N; Broun A; Ge K
    Mol Cell Biol; 2020 Sep; 40(20):. PubMed ID: 32817139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages.
    Li X; Zhang Q; Shi Q; Liu Y; Zhao K; Shen Q; Shi Y; Liu X; Wang C; Li N; Ma Y; Cao X
    J Autoimmun; 2017 Jun; 80():85-94. PubMed ID: 28284523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.
    Qiu H; Makarov V; Bolzenius JK; Halstead A; Parker Y; Wang A; Iyer GV; Wise H; Kim D; Thayaparan V; Lindner DJ; Haber GP; Ting AH; Ren B; Chan TA; Arora V; Solit DB; Lee BH
    Cancer Res; 2023 Mar; 83(6):814-829. PubMed ID: 36638328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
    Kalisz M; Bernardo E; Beucher A; Maestro MA; Del Pozo N; Millán I; Haeberle L; Schlensog M; Safi SA; Knoefel WT; Grau V; de Vas M; Shpargel KB; Vaquero E; Magnuson T; Ortega S; Esposito I; Real FX; Ferrer J
    EMBO J; 2020 May; 39(9):e102808. PubMed ID: 32154941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
    Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
    Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway.
    Yi Z; Wei S; Jin L; Jeyarajan S; Yang J; Gu Y; Kim HS; Schechter S; Lu S; Paulsen MT; Bedi K; Narayanan IV; Ljungman M; Crawford HC; Pasca di Magliano M; Ge K; Dou Y; Shi J
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):643-667. PubMed ID: 34583087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation.
    Gažová I; Lengeling A; Summers KM
    Mol Genet Metab; 2019 May; 127(1):31-44. PubMed ID: 31097364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic domain-dependent and -independent transcriptional activities of the tumour suppressor histone H3K27 demethylase UTX/KDM6A in specific cancer types.
    Sun W; Lee KL; Poellinger L; Masai H; Kato H
    Epigenetics; 2023 Dec; 18(1):2222245. PubMed ID: 37300822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
    Biswas M; Chatterjee SS; Boila LD; Chakraborty S; Banerjee D; Sengupta A
    FASEB J; 2019 Apr; 33(4):5268-5286. PubMed ID: 30668141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
    Lee SW; Park DY; Kim MY; Kang C
    Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. X chromosome protects against bladder cancer in females via a
    Kaneko S; Li X
    Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
    Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
    Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature.
    Abu-Hanna J; Patel JA; Anastasakis E; Cohen R; Clapp LH; Loizidou M; Eddama MMR
    Clin Epigenetics; 2022 Aug; 14(1):98. PubMed ID: 35915507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer.
    Yang J; Jin L; Kim HS; Tian F; Yi Z; Bedi K; Ljungman M; Pasca di Magliano M; Crawford H; Shi J
    Cancer Res; 2022 Nov; 82(22):4247-4260. PubMed ID: 36306422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy.
    Chen LJ; Xu XY; Zhong XD; Liu YJ; Zhu MH; Tao F; Li CY; She QS; Yang GJ; Chen J
    Bioorg Chem; 2023 Apr; 133():106409. PubMed ID: 36753963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.